Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:

• Introduction (00:00)
• Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)
• Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)
• Utility of Belantamab Mafodotin in R/R MM (49:29)
• Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)

CME information and select publications